Overview Energy plans to collect sunlight in orbit and send it to Earth, giving Meta early access to a new source of round-the-clock power
Updated
April 29, 2026 3:20 PM
A corona mass ejection erupts from our sun. PHOTO: UNSPLASH
Overview Energy, a startup focused on space-based power systems, has announced a new agreement with Meta to develop a new source of electricity for data centers. The partnership centres on space solar energy, with an orbital demonstration planned for 2028 and commercial power delivery targeted for 2030.
The deal gives Meta early access to as much as 1 gigawatt of future capacity from Overview’s system. That matters because large technology companies are searching for reliable power sources as demand rises from AI computing and data center expansion.
Overview’s idea is straightforward, though the engineering is ambitious. The company plans to place satellites in orbit that collect sunlight continuously in space. That energy would then be sent to existing solar sites on Earth, where it would be converted into electricity.
Unlike ground-based solar farms, which only generate power when the sun is shining locally, a space-based system is designed to extend power generation beyond daylight hours. In theory, this could help solar facilities produce electricity around the clock without using extra land.
"Space solar technology represents a transformative step forward by leveraging existing terrestrial infrastructure to deliver new, uninterrupted energy from orbit. We're excited to partner with Overview Energy to pioneer innovative energy solutions to advance our AI ambitions and infrastructure", said Nat Sahlstrom, VP of Energy and Sustainability, Meta. "This collaboration demonstrates our commitment to innovation – leveraging cutting-edge technology to strengthen America's energy leadership".
For Meta, the agreement is less about a near-term energy fix and more about securing future options. Major data center operators are increasingly competing for electricity as AI systems require more computing power and more cooling capacity. Traditional energy projects can take years to build, making alternative supply models more attractive.
Overview says its system is designed to work with solar projects that already exist. Instead of building entirely new power plants, the company aims to increase output from current sites by adding energy received from orbit.
"Space is becoming part of America's energy infrastructure", said Marc Berte, CEO of Overview Energy. "Our approach to space solar energy enables hyperscalers and technology providers to secure clean power with reliable siting, and speed to power.” "Together with Meta, we're looking beyond traditional constraints on where and when power can be delivered to meet the growing demand for electricity".
The larger significance of the partnership is what it signals about the energy market. As AI infrastructure expands, companies are beginning to look beyond conventional grids, gas plants and land-based renewables. Technologies once considered experimental are now being explored as part of long-term infrastructure planning.
There is still a long road ahead. Space solar power has been discussed for decades, but commercial deployment remains unproven. Launch costs, regulation and system reliability will all matter.
Even so, the Meta-Overview agreement shows how rising demand for constant power is reshaping where the technology sector looks for its next energy source.
Keep Reading
How a Korean biotech startup is using AI to move drug discovery from trial-and-error to precision design
A close up of a protein structure model. PHOTO: UNSPLASH
For decades, drug discovery has relied on trial and error, with scientists testing thousands of molecules to find one that works. Galux, a South Korean biotech startup, is changing that by using AI to design proteins from scratch. This method, called “de novo” design, makes it possible to build precise new therapies instead of searching through existing ones.
The company recently announced a US$29 million Series B funding round, bringing its total capital to US$47 million.This significant investment attracted a substantial roster of institutional backers, including the Korea Development Bank (KDB), Yuanta Investment, SL Investment and NCORE Ventures. These firms joined existing investors such as InterVest, DAYLI Partners and PATHWAY Investment, as well as new participants including SneakPeek Investments, Korea Investment & Securities and Mirae Asset Securities.
At the core of the company’s work is a platform called GaluxDesign. Unlike many AI tools that only predict how existing proteins fold, this system uses deep learning and physics to create entirely new therapeutic antibodies. This “from scratch” approach lets the team go after so-called “undruggable” proteins. These are targets that traditional small-molecule drugs can’t reach because they lack clear binding pockets. By designing proteins to fit these complex shapes, Galux aims to unlock treatments that have stayed out of reach for decades. And that’s exactly why investors are paying attention.
The pharmaceutical industry is actively looking for faster and more efficient ways to develop new drugs, and Galux is built for exactly that. The company connects its AI platform directly to its own wet lab, where designs can be tested in real time. Each result feeds straight back into the system, sharpening the next round of models. This continuous loop speeds up discovery and improves precision at every step. It’s also why partners like Celltrion, LG Chem and Boehringer Ingelheim are already working with Galux.
Galux is no longer just trying to make drugs that stick to a target. The company now wants its AI to design medicines that actually work in the body and can be made at scale. In simple terms, a drug has to do more than bind to a disease—it must be stable, safe and strong enough to change how the illness behaves. Galux is moving into tougher targets such as ion channels and GPCRs. These play key roles in heart function and sensory signals. Ultimately, the goal is to show that AI-driven design can turn complex biology into real treatments. And instead of hunting blindly for a solution, the team is building exactly what they need.